YZY Biopharma is a biopharmaceutical company specializing in tumor immunotherapy, focusing on the research, development and industrialization of bispecific antibody drugs. YZY Biopharma currently has more than ten products under research and development, covering tumor, infection, neurodegeneration and other fields, and has established a complete antibody drug development industry chain. For more information about YZY Biopharma, please visit www.yzybio.com.
VEGF+ANG2 Tetravalent Bispecific Antibody is a Class 1 Innovative Biological Product with a unique nanobody design for treatment of ocular fundus neovascular diseases, targeting VEGF (vascular endothelial growth factor) and ANG2 (angiopoietin 2), which effectively inhibits abnormal neovascularization through two different pathways. The Product enjoys the advantages of high affinity, strong inhibitory activity, high preparation concentration, good stability and low dosing frequency. It can reduce the potential risks caused by frequent intravitreal injections that occur to the patients and improve medication compliance of patients, possessing important clinical implications.
